53 results
Page 2 of 3
8-K
EX-99.1
s7tac07
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
19uqe67yy
12 Jul 22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
8:00am
8-K
EX-99.1
aylzmpx byzv
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
EX-99.1
jntsslce1atboijhra3
19 May 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
dnwfjr2849a0v0v4
9 May 22
VBI Vaccines Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
kjzbv4t4typhrtmf
29 Mar 22
VBI Vaccines Announces PreHevbrio™ is Now Available in the United States for the Prevention of Hepatitis B in Adults
8:00am
8-K
EX-99.1
uzq6ilq
7 Mar 22
VBI Vaccines Reports Fourth Quarter and Full Year Financial Results for 2021, Provides Corporate Update and Outlook for 2022
8:00am
8-K
EX-99.1
veuubkh fhzt
25 Feb 22
Regulation FD Disclosure
8:57am
8-K
EX-99.1
8u9vy clwve3ly18
23 Feb 22
Regulation FD Disclosure
4:05pm
8-K
EX-99.1
8t9bvhb
1 Dec 21
VBI Vaccines Announces FDA Approval of PreHevbrio™ for the Prevention of Hepatitis B in Adults
7:30am
424B5
pdb7a29an ymcdh
20 Sep 19
Prospectus supplement for primary offering
5:28pm
424B5
d5ut34e
18 Sep 19
Prospectus supplement for primary offering
4:04pm